Acelyrin started trading on the Nasdaq Friday morning in one of the largest biotech initial public offerings in recent memory, with $540 million in gross proceeds and potentially $621 million if underwriters exercise their 30-day option to buy more shares. Endpoints News dialed up Shao-Lee Lin, the California drug developer’s CEO, on Thursday night in advance of Acelyrin’s $SLRN listing, which priced at $18, the high end of its proposed range. Lin discusses Acelyrin’s pipeline plans, near-term data readouts, “thinking about what the next big thing is going to be,” and “hoping to break through the window” for other private startups to follow suit.
Read the full article: Q&A: Acelyrin CEO Shao-Lee Lin Details Biotech’s $540M IPO, Finding ‘Diamonds in the Rough’ //
Source: https://endpts.com/qa-acelyrin-ceo-shao-lee-lin-details-immunology-biotechs-540m-ipo